KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Debt to Equity (2016 - 2025)

Jazz Pharmaceuticals has reported Debt to Equity over the past 16 years, most recently at $1.24 for Q4 2025.

  • Quarterly Debt to Equity fell 16.85% to $1.24 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.24 through Dec 2025, down 16.85% year-over-year, with the annual reading at $1.24 for FY2025, 16.85% down from the prior year.
  • Debt to Equity was $1.24 for Q4 2025 at Jazz Pharmaceuticals, down from $1.35 in the prior quarter.
  • Over five years, Debt to Equity peaked at $2.09 in Q3 2022 and troughed at $0.55 in Q1 2021.
  • The 5-year median for Debt to Equity is $1.54 (2023), against an average of $1.53.
  • Biggest five-year swings in Debt to Equity: soared 201.65% in 2022 and later fell 21.49% in 2023.
  • Tracing JAZZ's Debt to Equity over 5 years: stood at $1.53 in 2021, then increased by 21.58% to $1.86 in 2022, then decreased by 17.59% to $1.53 in 2023, then fell by 2.39% to $1.49 in 2024, then decreased by 16.85% to $1.24 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at $1.24, $1.35, and $1.45 for Q4 2025, Q3 2025, and Q2 2025 respectively.